Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Moss

Showing results (271-280 of 308) with videos related to

Pageof 31
Sort By:
Journal of Virology|December 15, 2017
A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus MacaquesAndrew T Jones, Venkateswarlu Chamcha, Sannula Kesavardhana, et al.
Journal of Virology|February 6, 2015
CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus (SIV) vaccine enhances protection against neutralization-resistant mucosal SIV infectionSuefen Kwa, Shanmugalakshmi Sadagopal, Xiaoying Shen, et al.
Virology|August 19, 2007
GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccineLilin Lai, Dalma Vödrös, Pamela A Kozlowski, et al.
AIDS Research and Human Retroviruses|December 29, 2016
Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian VolunteersAgricola Joachim, Patricia J Munseri, Charlotta Nilsson, et al.
Virology|July 19, 2005
Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPsDennis Ellenberger, Linda Wyatt, Bin Li, et al.
Journal of Virology|December 13, 2002
Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251Koen K A Van Rompay, Jennifer L Greenier, Kelly Stefano Cole, et al.
Human Gene Therapy|June 6, 2018
DNA Vaccine-Induced Long-Lasting Cytotoxic T Cells Targeting Conserved Elements of Human Immunodeficiency Virus Gag Are Boosted Upon DNA or Recombinant Modified Vaccinia Ankara VaccinationXintao Hu, Antonio Valentin, Yanhui Cai, et al.
Journal of Virology|October 13, 2017
HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 VaccineXiaoying Shen, Rahul Basu, Sheetal Sawant, et al.
Open Forum Infectious Diseases|March 24, 2016
Strong, but Age-Dependent, Protection Elicited by a Deoxyribonucleic Acid/Modified Vaccinia Ankara Simian Immunodeficiency Virus VaccineVenkateswarlu Chamcha, Sunil Kannanganat, Sailaja Gangadhara, et al.
AIDS Research and Human Retroviruses|July 10, 2004
Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in MacaquesJames M Smith, Rama Rao Amara, Harold M McClure, et al.
Pageof 31

Showing results (271-280 of 308) with videos related to

Sort By:
Pageof 31
Journal of Virology|December 15, 2017
A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus MacaquesAndrew T Jones, Venkateswarlu Chamcha, Sannula Kesavardhana, et al.
Journal of Virology|February 6, 2015
CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus (SIV) vaccine enhances protection against neutralization-resistant mucosal SIV infectionSuefen Kwa, Shanmugalakshmi Sadagopal, Xiaoying Shen, et al.
Virology|August 19, 2007
GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccineLilin Lai, Dalma Vödrös, Pamela A Kozlowski, et al.
AIDS Research and Human Retroviruses|December 29, 2016
Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian VolunteersAgricola Joachim, Patricia J Munseri, Charlotta Nilsson, et al.
Virology|July 19, 2005
Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPsDennis Ellenberger, Linda Wyatt, Bin Li, et al.
Journal of Virology|December 13, 2002
Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251Koen K A Van Rompay, Jennifer L Greenier, Kelly Stefano Cole, et al.
Human Gene Therapy|June 6, 2018
DNA Vaccine-Induced Long-Lasting Cytotoxic T Cells Targeting Conserved Elements of Human Immunodeficiency Virus Gag Are Boosted Upon DNA or Recombinant Modified Vaccinia Ankara VaccinationXintao Hu, Antonio Valentin, Yanhui Cai, et al.
Journal of Virology|October 13, 2017
HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 VaccineXiaoying Shen, Rahul Basu, Sheetal Sawant, et al.
Open Forum Infectious Diseases|March 24, 2016
Strong, but Age-Dependent, Protection Elicited by a Deoxyribonucleic Acid/Modified Vaccinia Ankara Simian Immunodeficiency Virus VaccineVenkateswarlu Chamcha, Sunil Kannanganat, Sailaja Gangadhara, et al.
AIDS Research and Human Retroviruses|July 10, 2004
Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in MacaquesJames M Smith, Rama Rao Amara, Harold M McClure, et al.
Pageof 31